Coronary Stent Market Size Envisioned at USD 12.51 Billion by 2032

Coronary Stent Market Size and Top Leading Companies

The coronary stent market size was valued at USD 8.99 billion in 2023 and is anticipated to reach USD 12.51 billion by 2032, registering a significant growth with a 3.6% of CAGR (2024-2032).

Unlock Infinite Advantages: Subscribe to Annual Membership

Report Highlights:

• Drug-eluting stents (DES) dominated the market with a 60% market share in 2023.
• North America led the market in 2023 with 37%.
• Bioresorbable Scaffold Systems (BRS) are projected to be the fastest-growing type with 5.2% CAGR over the forecast period.

Coronary stents are mostly preferred in coronary artery diseases which is the most significantly driving the coronary stent market.

Coronary stents are medical devices majorly used in most angioplasty (a procedure used to open clogged coronary arteries due to coronary artery disease) procedures. Coronary arteries when clogged because of underlying atherosclerosis disease, these coronary stents are used. This procedure of introduction of coronary stents is called percutaneous coronary intervention (PCI). The coronary stent market began in the late 1980s, with the development of the first balloon-expandable stents. These devices transformed the treatment of coronary artery disease (CAD), which is the leading cause of death worldwide. CAD is caused by the accumulation of plaque in the coronary arteries, which restricts blood flow to the heart. This can cause chest pain (angina), heart attacks and heart failure.

Traditional treatment included bypass surgery, which was a very invasive procedure. Coronary stents are tiny expandable mesh tubes inserted into narrowed coronary arteries to prop them open and improve blood flow.

Percutaneous coronary intervention (PCI), also known as angioplasty with stenting, is a minimally invasive procedure using catheters to deliver and implant the stent.

Growing CAD Burden Fuels the Demand for Coronary Stents

Coronary artery disease (CAD) is a huge danger to world health, killing millions each year. It is characterized by plaque formation in the coronary arteries, which are crucial for providing oxygen-rich blood to the heart muscle. This plaque constricts the arteries, limiting blood flow and potentially causing chest pain (angina), heart attacks, and cardiac failure. The increasing demand for coronary stents is mostly driven by the growing burden of CAD.

As the world's population ages, the risk of CAD inevitably rises. Older people are more likely to acquire plaque formation as a result of wear and strain on the body's systems. This growing generation creates a greater pool of potential patients who may require coronary stenting treatments. Modern lifestyles greatly contribute to the rise of CAD. Unhealthy diets heavy in saturated fat, cholesterol, and processed sugars are well-known risk factors. Furthermore, a lack of physical activity, smoking, and high-stress levels exacerbate the condition. As these lifestyle patterns continue, the prevalence of CAD is expected to increase.

Diabetes is a significant risk factor for CAD. The global diabetes epidemic has considerably increased the population's susceptibility to coronary artery problems. Diabetics have metabolic changes that increase plaque formation in the arteries, making them more likely to require coronary stents to restore blood flow.

Less Invasive and Faster Recovery Options Drives Coronary Stent Market

The coronary stent market has expanded dramatically in recent years, owing mostly to the growing desire for minimally invasive and rapid recovery treatment options for coronary artery disease (CAD).

Traditional therapy for clogged coronary arteries included bypass surgery, which required a huge incision in the chest cavity. While efficient, this procedure has substantial downsides, including extensive surgical trauma, lengthy hospital stays, and extended recovery durations. Coronary stenting, on the other hand, provides a significantly less intrusive alternative. The technique entails introducing a catheter through a small incision in the groin or arm and guiding it to the occluded artery. Once positioned, a deflated stent is inserted and expands, keeping the artery open and improving blood flow.

This minimally invasive method has various benefits for patients:

• Reduced Pain and Discomfort: Compared to bypass surgery, smaller incisions provide less post-operative pain and discomfort.
• Shorter Hospital Stays: following stenting, patients often spend less time in the hospital than following bypass surgery.
• Faster Recovery: Minimally invasive procedures enable a quicker return to everyday routines and a higher quality of life.

The less invasive nature of stenting treatments results in speedier recovery times for patients. This is an important consideration for people who cannot tolerate the rigours of major surgery or who want to return to work and daily activities as soon as possible. Faster healing also lowers the overall healthcare expenses associated with prolonged hospital stays.

The coronary stent market has profited greatly from ongoing improvements in stent design and materials. Early stents were prone to restenosis, which occurs when the artery re-narrows after the surgery. Drug-eluting stents (DES) were a significant advancement, using slow-releasing medication to avoid restenosis and enhance long-term patency rates. Newer developments, such as bioresorbable stents that disintegrate over time, are being studied to provide further benefits.

The increased need for minimally invasive operations and faster recovery periods, together with developments in stent technology, are projected to drive the coronary stent market. As the global burden of CAD grows due to an aging population, poor lifestyles, and rising diabetes rates, the need for effective treatment alternatives such as coronary stenting is expected to stay high.

Furthermore, continuous research and development in stent technology point to even more successful and patient-friendly treatments in the future. This ongoing innovation, combined with the growing demand for minimally invasive procedures, is likely to drive the coronary stent market to new heights.

Technological Advancements Revolutionizing Coronary Stent Design

Coronary stents have seen tremendous changes since their introduction in the late 1980s. Early bare-metal stents (BMS) were a substantial improvement over traditional bypass surgery, providing a less intrusive option for treating clogged coronary arteries. However, restrictions such as restenosis (re-narrowing of the artery) fueled innovation in stent design, resulting in a wave of technological breakthroughs.

Drug-Eluting Stents (DES)

• While bare-metal stents were effective in opening arteries, they were prone to restenosis caused by scar tissue growth. This often necessitated several surgeries. DES transformed the field by integrating medication inside the stent struts. These medications are gradually delivered over time, inhibiting cell proliferation and lowering the risk of restenosis.

Biocompatible Coatings

• Early stents may cause inflammation in some individuals, leading to problems. Stent producers created biocompatible coatings to reduce tissue irritation and increase long-term results. These coatings improve healing and lower the risk of stent thrombosis.

Stent Design and Flexibility

• Early stents were inflexible and may not have fully conformed to the unique structure of each patient's coronary artery. This could lead to complications such as stent malapposition (incomplete contact with the arterial wall). Advanced stent designs include more flexibility to accommodate diverse vessel shapes and diameters. Closed-cell stent designs with laser-cut patterns also improve flexibility and provide more uniform drug delivery.

Focus on Cost Effectiveness with Coronary Stents

When it comes to cardiac stents, cost-effectiveness is achieved by a delicate balance of optimizing patient care and managing healthcare spending. Encouraging the adoption of generic stents, which provide comparable efficacy to branded stents at a cheaper cost, is a significant cost-cutting strategy. Regulatory agencies can streamline the approval procedure for high-quality generic stents. Moving away from price-based models and towards value-based pricing can encourage manufacturers to create stents with better long-term results and fewer problems, potentially lowering overall healthcare costs.

Hospitals and healthcare institutions can arrange bulk purchasing agreements with stent producers to get better prices. Carefully selecting patients who will gain the most from stenting treatments, taking into account criteria like as disease severity and overall health, can help to avoid unnecessary procedures and expenditures. Streamlining procedures and reducing procedural durations can help to reduce operating room costs and resource utilization. Implementing programs to manage post-procedural care and lower hospital readmission rates can have a major influence on overall healthcare expenses.

While these stents may have a greater initial cost, their ability to minimize the need for subsequent operations due to permanent implant difficulties can result in long-term cost benefits. Creating stents with longer lifespans and reduced re-intervention rates can lessen the need for recurrent treatments and their associated expenses. Investing in research and development of stents with higher efficacy and lower complication rates can result in cost savings by minimizing the need for subsequent treatments.

Manufacturers, clinicians, hospitals, insurers, and regulatory agencies can collaborate to design and implement methods that encourage the cost-effective use of coronary stents while maintaining good patient care standards. Exploring risk-sharing arrangements in which manufacturers share some of the financial burden associated with problems or re-interventions may encourage them to create stents with better long-term outcomes.

Cost-effectiveness in the coronary stent market necessitates a multifaceted approach. Implementing these techniques allows stakeholders to ensure patients receive the best possible treatment while responsibly controlling healthcare expenses. It's crucial to remember that cost-effectiveness should never come at the expense of patient safety or good treatment outcomes. The goal is to achieve a sustainable balance that benefits both patients and healthcare systems.

Geographical Landscape

The coronary stent market landscape varies by geography, with some regions dominating and others showing great development potential. North America now dominates the global market for coronary stents.

Several causes contribute to their dominance, including:

• CAD has a high prevalence due to factors such as poor lifestyles and the aging population.
• Advanced healthcare infrastructure and access to modern technologies.
• High rates of insurance coverage for stent surgeries.

Europe is a well-developed market for coronary stents with intense competition. Stringent regulatory frameworks and an emphasis on cost-effectiveness may have an impact on pricing and market trends.

European firms are actively engaged in the research and development of innovative stent technologies, including bioresorbable stents.

The geographical landscape of the coronary stent market is dynamic and changing. While North America now enjoys the leading position, the Asia Pacific area offers promising growth opportunities. Technological developments and a focus on cost-effectiveness are major trends influencing the future of this industry in all geographic regions.

Coronary Stent Market Companies

• Biotronik SE & Co. KG
• Cook
• Terumo Corporation
• Abbott
• BD
• MicroPort Scientific Corporation
• B. Braun Melsungen AG
• Boston Scientific Corporation
• Medtronic

Coronary Stent Market Segments

(**We also provide cross-sectional analysis in market segments)

By Type

• Bare Metal Stents (BMS)
• Drug-eluting Stents (DES)
• Bioresorbable Scaffold System (BRS)
• Drug-eluting Balloons (DEB)

By End Use

• Hospitals & Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Geography

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America